#1 Clinical Trials Search in Europe

Cefoxitin Sodium

This article examines the use of Cefoxitin Sodium in various clinical trials. Cefoxitin is an antibiotic used to treat and prevent bacterial infections. The trials discussed here explore its effectiveness in different medical scenarios, including urinary tract infections, surgical prophylaxis, and postpartum care. By reviewing these studies, we can better understand how Cefoxitin compares to other antibiotics and its potential benefits in clinical practice.

Table of Contents

What is Cefoxitin?

Cefoxitin sodium, also known simply as cefoxitin, is an antibiotic medication. It belongs to a class of antibiotics called cephamycins, which are related to cephalosporins[1]. Cefoxitin was developed in the 1970s but its use declined when newer, broader-spectrum antibiotics became available. However, due to the rise of antibiotic-resistant bacteria, there has been renewed interest in cefoxitin as a potential treatment option[1].

Uses of Cefoxitin

Cefoxitin is used to treat various bacterial infections. Some of the conditions it’s used for include:

  • Urinary tract infections (UTIs): Cefoxitin is being studied for treating UTIs caused by certain types of bacteria, particularly those that are resistant to other antibiotics[1].
  • Surgical site infections: It’s used to prevent infections after certain types of surgery, such as colorectal surgery[2].
  • Pelvic infections: Cefoxitin may be used to treat infections in the pelvic area, including those that occur after childbirth[3].
  • Intra-abdominal infections: Some studies are looking at its use in treating infections within the abdominal cavity[4].

How Cefoxitin is Administered

Cefoxitin is typically given intravenously (through a vein) in a hospital or clinical setting. The dosage and frequency can vary depending on the specific condition being treated and the patient’s individual factors. Some common administration methods include:

  • Single dose: For preventing surgical infections, a single dose may be given before surgery[2].
  • Multiple doses: For treating active infections, multiple doses may be given over several days[1].
  • Continuous infusion: Some studies are looking at giving cefoxitin as a continuous infusion over several hours[2].

Effectiveness of Cefoxitin

Cefoxitin has shown effectiveness against various types of bacteria, including some that are resistant to other antibiotics. It’s particularly useful against a type of antibiotic-resistant bacteria called extended-spectrum β-lactamase (ESBL) producing Escherichia coli[1]. This makes it a valuable option when other antibiotics don’t work.

In surgical settings, studies are ongoing to determine if cefoxitin is more effective than other antibiotics in preventing infections. For example, one study is comparing cefoxitin to piperacillin-tazobactam for preventing infections after pancreatic surgery[5].

Ongoing Research on Cefoxitin

Several clinical trials are currently underway to further understand the effectiveness and best uses of cefoxitin. Some areas of research include:

  • Optimal dosing: Researchers are studying the best ways to administer cefoxitin, including comparing continuous infusion to intermittent dosing[2].
  • Use in obese patients: One study is looking at how obesity affects the concentration of cefoxitin in the body and whether dosage adjustments are needed[4].
  • Comparison to other antibiotics: Studies are comparing cefoxitin to other antibiotics to determine which is most effective for various conditions[5].

Potential Side Effects

Like all medications, cefoxitin can cause side effects. While not everyone experiences side effects, it’s important to be aware of the possibilities. Common side effects may include:

  • Nausea or vomiting
  • Diarrhea
  • Allergic reactions (in people allergic to penicillin or cephalosporins)

It’s important to discuss any concerns about side effects with your healthcare provider. They can provide more detailed information based on your specific health situation[6].

Study Focus Comparator Drug(s) Patient Population Primary Outcome
Urinary tract infections Imipenem/cilastatin Women with ESBL-producing E. coli infections Bacteriological non-inferiority
Colorectal surgery prophylaxis Continuous vs. intermittent administration Patients undergoing colorectal surgery Surgical site infection rate
Pancreatoduodenectomy prophylaxis Piperacillin-tazobactam Patients undergoing pancreatoduodenectomy Postoperative surgical site infection rate
Postpartum infection prevention Placebo HIV-positive pregnant women Incidence of postpartum infectious morbidity
Perineal tear repair Placebo Women with 3rd/4th degree perineal tears Perineal breakdown or infection rate

FAQ

  • What is Cefoxitin Sodium used for in clinical trials? Cefoxitin Sodium is being studied for various uses, including treating urinary tract infections caused by ESBL-producing E. coli, preventing surgical site infections in colorectal and pancreatic surgeries, and reducing postpartum infections in HIV-positive women.
  • How is Cefoxitin administered in these trials? Administration methods vary by study. Some trials use intravenous bolus doses (e.g., 2g every 6 hours), while others explore continuous infusion. The timing and duration of treatment also differ based on the specific medical scenario being investigated.
  • What are some of the comparator drugs used alongside Cefoxitin in these trials? Comparator drugs include imipenem/cilastatin for urinary tract infections, piperacillin-tazobactam for surgical prophylaxis, and placebo in some studies to assess Cefoxitin's effectiveness.
  • What are the primary outcomes measured in Cefoxitin clinical trials? Primary outcomes often include rates of infection (e.g., surgical site infections, postpartum infections), clinical and microbiological response to treatment, and in some cases, pharmacokinetic/pharmacodynamic parameters of the drug.
  • Are there any specific patient populations being studied with Cefoxitin? Yes, the trials focus on various patient groups, including women with urinary tract infections, patients undergoing colorectal or pancreatic surgery, HIV-positive pregnant women, and women with postpartum perineal tears.

Ongoing Clinical Trials on Cefoxitin Sodium

  • Study on Cefoxitin and Sodium Chloride for Preventing Infections After Colorectal Surgery

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • ESBL-producing E. coli: Escherichia coli bacteria that produce extended-spectrum beta-lactamases, enzymes that can break down many common antibiotics, making these infections more difficult to treat.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys, often causing fever, back pain, and other symptoms.
  • Surgical site infection (SSI): An infection that occurs after surgery in the part of the body where the surgery took place.
  • Prophylactic antibiotics: Antibiotics given to prevent infections, often before or during surgery.
  • Pharmacokinetic/Pharmacodynamic (PK/PD) parameters: Measurements that describe how the body processes a drug (pharmacokinetics) and how the drug affects the body (pharmacodynamics).
  • Puerperal sepsis: A serious infection of the genital tract that can occur after childbirth.
  • Microdialysis: A technique used to measure the concentration of substances in the fluid between cells in various tissues.
  • Carbapenem: A class of antibiotics used to treat a wide variety of bacterial infections, often reserved for more serious cases.
  • Cephamycin: A subclass of antibiotics related to cephalosporins, which includes cefoxitin.
  • Neutrophil: A type of white blood cell that plays a crucial role in fighting bacterial infections.

References

  1. https://clinicaltrials.gov/study/NCT01820793
  2. https://clinicaltrials.eu/trial/study-on-cefoxitin-and-sodium-chloride-for-preventing-infections-after-colorectal-surgery/
  3. https://clinicaltrials.gov/study/NCT00343317
  4. https://clinicaltrials.gov/study/NCT03306290
  5. https://clinicaltrials.gov/study/NCT03269994
  6. https://clinicaltrials.gov/study/NCT00186082